TARA

Protara Therapeutics

Fundamental data last updated:April 13, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

Nasdaq

County of HQ

United States

Next Earnings Date

05/14/26

Business Summary

Protara Therapeutics is a clinical-stage biotechnology company focused on developing specialized therapeutics, typically targeting rare or underserved diseases. The business model centers on advancing drug candidates through clinical trials to unlock regulatory approval and commercialization or partnership milestones. Cash generation, when it occurs, typically comes from licensing agreements, milestone payments, or eventual product sales rather than diversified operating income. The moat, if achieved, would stem from intellectual property protection, regulatory exclusivity, and niche market positioning rather than scale economics.

 


Analyze TARA on TradingView

VALUATION

P/E

-

Market Cap ($M USD)

$268

Forward P/E

-

PEG

-

PRICE TO SALES

-

PRICE TO BOOK

1.4

EV / EBITDA

-1.8

5-Year Average P/E

Free Cash Flow Yield

DCF Value

Graham Number

Price to FCF

EV to FCF

Earnings Yield

FCF Yield

DIVIDEND

Yield

-

Annual Payout

-

Payout Ratio

-

Consecutive Years of Dividend Growth

0

5-Year Dividend Growth Rate

-

Financial Health & Profitability

Earnings Per Share

-$1.34

Next Year EPS Growth Estimate

-$1.39

Next Year Revenue Growth Estimate

-

Return on Equity (ROE)

-29.20%

FREE CASH FLOW

Operating Margin

-

Debt-to-Equity

0

Piotroski F-Score

3

Altman Z-Score

10.1

Return on Invested Capital (ROIC)

-34.30%

Current Ratio

14.6

Quick Ratio

Net Debt to EBITDA

Interest Coverage

Gross Profit margin

FCF PER SHARE

REVENUE PER SHARE

Analyze TARA on TradingView

Gainseekers Quantitative Analysis

Summary

This is a pre-revenue, loss-generating biotechnology micro-cap with a $268M market cap trading at 1.4x book and producing an EPS of -1.8 with next year estimated at -$1.34. The absence of a P/E and Forward P/E reflects a company still firmly in the red, but the Altman Z-Score of 10.1 signals exceptionally low near-term bankruptcy risk, reinforced by a very strong 14.6 current ratio. The market is not pricing in profitability; it is pricing in optionality. This is not a conventional growth story—it is a balance-sheet-backed clinical bet where survival odds are strong, but operating performance remains deeply negative with a -29.20% operating margin and -34.30% ROIC.

AI Exposure / Tech Reliance

As a biotechnology company in Healthcare, Protara Therapeutics operates in a sector where AI-driven drug discovery, biomarker identification, and trial optimization are becoming standard competitive tools. Biotechnology firms that integrate computational modeling into development pipelines can accelerate timelines and reduce burn rates. While no specific AI metrics are provided, the industry backdrop suggests technology adoption is more opportunity than threat.

The Bull Case

A deep value or speculative GARP investor buys this for balance sheet strength and asymmetry. A 14.6 current ratio combined with an Altman Z-Score of 10.1 is fortress-level liquidity for a company with negative earnings, dramatically lowering insolvency risk. EPS is projected to improve from -1.8 to -$1.34, indicating narrowing losses, and at 1.4x book, the market is not assigning aggressive pipeline premiums. The Piotroski F-Score of 3 is weak, but in biotech, liquidity and survival matter more than traditional profitability metrics—this is a call option with a long runway.

The Bear Case

The red flags are obvious and structural. Operating margin sits at -29.20% and ROIC at -34.30%, meaning capital is currently being destroyed, not compounded. There is no P/E, no Forward P/E, no PEG, no yield, and no dividend support—investors are entirely dependent on future clinical success. Sales Growth Next Year is listed at -$1.39, which signals either minimal revenue visibility or continued contraction dynamics, reinforcing that this is a binary outcome equity rather than a stable compounder.

Market Sentiment & Smart Money

Short Interest %

12.00%

Analyst Consensus

1.22

Average Analyst Price Target

$25.71

Institutional Ownership %

78.60%

1-Year Beta

1.18

Insider Buying % (6 Mo)

2.10%%

Distance to 52-Week High

63.40%

Distance to 52-Week Low

179.10%

EARNINGS SURPRISE %

50-DAY SMA

200-DAY SMA

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.